the boundary was finally crossed again at patient 51, and the procedure remained under control since. Conclusions: The failure of a TAVI procedure may be due to several factors, many of which are not directly related to the operative technique itself. By allowing the early identification of negative trends, the CUSUM charts may prompt internal audits aimed to the identification of the causes of failure, helping to take the procedure back into control.
Background: SAVR is the standard procedure for symptomatic aortic stenosis while TAVI is the method of choice in patients at high risk. It is gaining increasing importance in intermediate risk patients but to date there are limited data to assess benefits and risks. Methods: Analyses were based on the TAVIK registry of patients undergoing TAVI or SAVR between 2007 and 2012. For this analysis only patients with a logistic EuroSCORE (ES) 15 were considered. Both groups were compared using Propensity Score Matching. Results: As of April 2012 a total of 1,825 patients (1,003 TAVI/822 SVAR) were included into TAVIK. 1,141 had a ES 15 (419 TAVI/722 SAVR). The mean ES was 10.1AE2.8 in the TAVI and 5.7AE3.2 in the SAVR (p<0.0001). 3-yaers Survival was higher in SVAR (p¼0.0023). 432 patients were considered for the matched-pairs analysis based on the propensity score. The mean ES was 8.7AE2.7 and 8.8AE2.8 respectively (p¼0.52). Major vascular complications (10.6% vs. 0.0%; p<0.0001), new pacemaker implantation (13.9% vs. 4.6%; p<0.001) and moderate aortic insufficiency (3.2% vs. 0.5%; p¼0.03) were more in TAVI. Major (20.8% vs. 4.2%; p<0.0001) and life-threatening (14.5% vs. 2.3%; p<0.0001) bleeding complications were more in SVAR. Survival probability over three years in the propensity matched cohort comparable between both groups (Log-Rank test p¼0.2196).
Conclusions: Based on one of the largest single center "real world" datasets (TAVIK), we were not able to show a differential prognosis for intermediate risk patients undergoing transcatheter or surgical aortic valve replacement after adjusting for baseline risk.
MedStar Health Research Institute, Washington, DC
Background: The impact of left geometric adaptive patterns in patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) has not been established. Methods: The left ventricular mass (LVMi) and the relative wall thickness (RWT) were indexed to the body surface area and gender. A normal LVMi was considered 95 g/m2 in women and 115 g/m2 in men. Normal LVg was considered if LVMI was normal and RWT was 0.42. Concentric hypertrophy was defined as LVMI above the threshold together with RWT >0.42, but if RWT was below this cut-off, eccentric hypertrophy was present. Concentric remodeling was defined when the LVMi was normal but RWT >0.42. Valve Academic Research Consortium (VARC) criteria were used for procedural success. We compared the mortality rates at 1 year by the Kaplan-Meier method. Results: A total of 357 consecutive patients underwent TAVR. Normal geometry was present in 10% of patients while concentric remodeling, concentric hypertrophy and eccentric hypertrophy were present in 40%, 41% and 9%, respectively. The age, baseline clinical characteristics, STS score and the VARC success rates were similar among the different types of left geometry. The 1-year estimated mortality according to ventricular geometry is shown in the Figure. (Log-Rank p <0.01) Conclusions: The post-procedural left ventricular geometry adaptive pattern in patients undergoing TAVR is associated with 1-year mortality. The concentric remodeling represents the higher risk subgroup. Left ventricular geometry should be followed in all patients post TAVR. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5 :30 PM
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Comparison of long-term clinical outcome between patients with chronic versus acute type B aortic dissection treated by implantation of a stent graft: a single-center report Shao Liang Chen 1 1 Nanjing First Hospital, Nanjing Medical University, Jiangsu, China Background: Background: Stent grafting for treatment of type B aortic dissection has been extensively used. However, the difference in the long-term clinical outcome between patients with chronic versus acute type B aortic dissection remains unknown. This study aimed to analyze the difference in long-term clinical outcome after endovascular repair for patients with chronic ($2 weeks) versus acute (<2 weeks) type B aortic dissection. Methods: Between May 2000 and June 2011, a total of 174 patients with type B aortic dissection (56 chronic, 118 acute) treated by endovascular repair were studied prospectively. Follow-up three-dimensional computed tomography scanning and aortoangiography were scheduled at 3-6 months after the index procedure. Propensity score matching was used to compare the difference in the endpoint between the two groups. Results: The procedure-related event rate was 18.6% in the acute group and 5.4% in the chronic group (P ¼ 0.021), but this difference became nonsignificant after propensity score matching. At the end of follow-up (mean 2.49 years), overall and aorta-related mortality was 11.0% and 7.6%, respectively, in the acute group, and was not significantly different from that in the chronic group (3.6% and 3.6%, P ¼ 0.148 and P ¼ 0.506, respectively). Both false and true lumina showed significant remodeling over time, with .93% complete false-lumen thrombosis. Untreated tear and type I endoleak were predictors of clinical events during follow-up. Conclusions: Comparable long-term clinical results were achieved in patients with chronic or acute type B aortic dissection after implantation of a stent graft.
TCT-742
Lower 20%, p¼0.03) , and a trend toward fewer overall vascular complications (17% vs. 26%, p¼0.06). More patients with vascular complications in the percutaneous cohort had minimal artery diameter (MAD) less than sheath OD (74% versus 55%, p¼0.03). The percutaneous group had decreased length of stay (LOS) compared to the open group (7.5 AE 4.7 vs. 9.9 AE 9.9 days, p¼0.003). There was no difference in in-hospital mortality between the open and percutaneous groups (2.5 % vs. 1 %, p¼0.36). The use of second generation TAVR sheaths and valves via a percutaneous approach was associated with an even greater reduction in vascular complications (8% vs. 25%, p¼0.01) and LOS (7.0 AE 4.8 versus 10.1 AE 10.0 days, p¼0.04) as compared to the open group with first generation devices. Despite an increase in the difference between sheath OD and MAD (-0.21 vs. 0.27 mm, p¼0.02) in the first and second half of our percutaneous access experience, the rates of vascular complications did not change over this time. Conclusions: TF TAVR via a percutaneous approach is associated with less vascular morbidity and lower LOS as compared to an open surgical approach. These benefits are even greater with second-generation (Sapien XT) devices.
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Stratification of survival after transcatheter aortic valve replacement based on vascular complication by VARC-1 or VARC-2 criteria Kazuaki Okuyama 1 , Hasan Jilaihawi 1 , Mohammad Kashif 1 , Omar R. Sadruddin 1 , Jigar Patel 1 , Vikas Soni 1 , Heera Pokhrel 1 , Tarun Chakravarty 2 , Mamoo Nakamura 1 , Raj Makkar 1 1 Cedars-Sinai Medical Center, Los Angeles, CA, 2 Cedars Sinai Medical Center, Los Angeles, CA Background: Valve academic research consortium (VARC) guidelines were devised in an effort not only to standardize clinical endpoint definitions but also to select endpoints that best reflect the safety and efficacy of transcatheter aortic valve replacement (TAVR). These guidelines are evolving in an expert led manner. We sought to compare the predictive value for survival of major vascular complications (VC) by VARC-1 and 2 definitions. Methods: A large single center series of patients undergoing TAVR by multiple approaches were studied. We defined VC according to VARC-1 and VARC-2 definition, and compared the mortality one year after the procedure. Data was analyzed using Kaplan-Meier (KM) and Cox regression multivariable models that included all variables related to 1-year mortality to a significance level 0.1. Results: Data was analyzed for 388 patients. KM curves showed a numerically lower survival rate at 1-year by major VC with both definitions, but only VARC-2 had statistical significance; 79.2% vs. 60.7% with VARC-2 (p ¼0.015), and 78.8% vs. 70.5% with VARC-1 (p ¼ 0.211). Cox regression multivariable model showed VC by VARC-2 definition to be an independent predictor of 1-year mortality (p ¼ 0.004), but not when VC was substituted by the VARC-1 definition (p¼0.08). Conclusions: The VARC-2 definition for vascular complications offers better stratification of survival than the VARC-1 definition, supporting its widespread use. Reasons for this important difference will be discussed. Background: Although prior studies describe the fluoroscopic operator-independent motion of the balloon-expandable valve, no studies have described the transesophageal echocardiogram (TEE) appearance of valve deployment. Methods: Intraoperative TEE from 100 consecutive* patients presenting for TAVR were retrospectively analyzed. Patients with unreliable pacemaker capture or obvious operator-induced device motion during deployment were excluded (n¼16). Device position was defined as the percent of total device height below the virtual annulus (hinge points of aortic valve cusps). Device position was measured pre-deployment (during rapid pacing) and post-deployment. Device cranial movement during deployment was defined as the difference between the pre-deployment and postdeployment position (in mm) of the valve midpoint. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
